1. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Results from the 2016 National Survey on Drug Use and Health: detailed tables. Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH-DetTabs-2016.pdf. Published September 7, 2017. Accessed September 13, 2018.
2. Jones E, Fear NT. Alcohol use and misuse within the military: a review. Int Rev Psychiatry. 2011;23(2):166-172.
3. Fuehrlein BS, Mota N, Arias AJ, et al. The burden of alcohol use disorders in US military veterans: results from the National Health and Resilience in Veterans Study. Addiction. 2016;111(10):1786-1794.
4. Stahre MA, Brewer RD, Fonseca VP, Naimi TS. Binge drinking among US active-duty military personnel. Am J Prev Med. 2009;36(3):208-217.
5. Institute of Medicine. Substance use disorders in the U.S. armed forces. https://www.nap.edu/resource/13441/SUD_rb.pdf. Published September 2012. Accessed September 12, 2018.
6. McDevitt-Murphy ME, Murphy JG, Williams JL, Monahan CJ, Bracken-Minor KL. Brief intervention to reduce hazardous drinking and enhance coping among OEF/OIF/OND veterans. Prof Psychol Res Pr. 2015;46(2):83-89.
7. Jacobson IG, Ryan MA, Hooper TI, et al. Alcohol use and alcohol-related problems before and after military combat deployment. JAMA. 2008;300(6):663-675.
8. Chou SP, Dawson DA, Stinson FS, et al. The prevalence of drinking and driving in the United States, 2001-2002: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend. 2006;83(2):137-146.
9. Bazargan-Hejazi S, Bazargan M, Hardin E, Bing EG. Alcohol use and adherence to prescribed therapy among under-served Latino and African-American patients using emergency department services. Ethn Dis. 2005;15(2):267-275.
10. Kamali M, Kelly BD, Clarke M, et al. A prospective evaluation of adherence to medication in first episode of schizophrenia. Eur Psychiatry. 2006;21(1):29-33.
11. Tucker JS, Burnam MA, Sherbourne CD, Kung FY, Gifford AL. Substance abuse and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med. 2003;114(7):573-580.
12. Rehm J, Room R, Graham K, Monteiro M, Gmel G, Sempos CT. The relationship of average volume of alcohol consumption and patterns of drinking to burden of disease: an overview. Addiction. 2003;98(9):1209-1228.
13. Kendler KS, Ohlsson H, Sundquist J, Sundquist K. Alcohol use disorder and mortality across the lifespan: a longitudinal cohort and co-relative analysis. JAMA Psychiatry. 2016;73(6):575-581.
14. Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States. Arch Gen Psychiatry . 2007;64(7):830-842.
15. Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004;61(8):807-816.
16. Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014;311(18):1889-1900.
17. Del Re AC, Gordon AJ, Lembke A, Harris AH. Prescription of topiramate to treat alcohol use disorders in the Veterans Health Administration. Addict Sci Clin Pract. 2013;8:12.
18. Harris AH, Ellerbe L, Reeder RN, et al. Pharmacotherapy for alcohol dependence: perceived treatment barriers and action strategies among Veterans Health Administration service providers. Psychol Serv. 2013;10(4):410-419.
19. ReVia [package insert]. Pomona, NY: Duramed Pharmaceuticals; 2013.
20. US Department of Veterans Affairs, Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives. Alcohol use disorder pharmacotherapy: naltrexone, acamprosate, and disulfiram recommendations for use. https://www.pbm.va.gov/PBM/clinicalguidance/clinicalrecommendations/Alcohol_Use_Disorder_Pharmacotherapy_Acamprosate_Naltrexone_Disulfiram_Recommendations_for_Use.docx. Published December 2013. Accessed September 17, 2018.
21. Anton RF. Naltrexone for the management of alcohol dependence. N Engl J Med. 2008;359(7):715-721.
22. O’Malley SS, Rounsaville BJ, Farren C, et al. Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials. Arch Intern Med. 2003;163(14):1695-1704.
23. O’Brien CP. A range of research-based pharmacotherapies for addiction. Science. 1997;278(5335):66-70.
24. Swift RM. Effect of naltrexone on human alcohol consumption. J Clin Psychiatry. 1995;56 (suppl 7):24-29.
25. Center for Substance Abuse Treatment. Incorporating Alcohol Pharmacotherapies into Medical Practice. Treatment Improvement Protocol (TIP) Series 49. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2009.
26. Spanagel R, Zieglgänsberger W. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci. 1997;18(2):54-59.
27. Herz A. Endogenous opioid systems and alcohol addiction. Psychopharmacology (Berl). 1997;129(2):99-111.
28. Miller NS. The integration of pharmacological and nonpharmacological treatments in drug/alcohol addiction. J Addict Dis. 1997;16(4):1-5.
" class="smart-paging drupal-content" src="/sites/all/modules/contrib/smart_paging/plugins/wysiwyg/smart_paging/images/spacer.gif" title="<--pagebreak-->">29. Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 2013;108(2):275-293.
30. Bouza C, Angeles M, Muñoz A, Amate JM. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction. 2004;99(7):811-828.
31. Anton RF, O’Malley SS, Ciraulo DA, et al; COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003-2017.
32. Oslin DW, Pettinati HM, Volpicelli JR, Wolf AL, Kampman KM, O’Brien CP. The effects of naltrexone on alcohol and cocaine use in dually addicted patients. J Subst Abuse Treat. 1999;16(2):163-167.
33. Kranzler HR, Wesson DR, Billot L; DrugAbuse Sciences Naltrexone Depot Study Group. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res. 2004;28(7):1051-1059.
34. Bryson WC, McConnell J, Korthuis PT, McCarty D. Extended-release naltrexone for alcohol dependence: persistence and healthcare costs and utilization. Am J Manag Care. 2011;17 (suppl 8):S222-S234.
35. Vivitrol [package insert]. Waltham, MA: Alkermes, Inc.; 2010.
36. Campral [package insert]. St. Louis, MO: Forest Laboratories Inc; 2012.
37. Paille F, Guelfi J, Perkins AC, Royer RJ, Steru L, Parot P. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol. 1995;30(2):239-247.
38. Pelc I, Verbanck P, Le Bon O, Gavrilovic M, Lion K, Lehert P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiatry . 1997;171:73-77.
39. Sass H, Soyka M, Mann K, Zieglgänsberger W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry. 1996;53(8):673-680.
40. Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res. 2004;28(1):51-63.
41. Mason BJ, Lehert P. Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data. Alcohol Clin Exp Res. 2012;36(3):497-508.
42. Richardson K, Baillie A, Reid S, et al. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol? Addiction. 2008;103(6):953-959.
43. Antabuse [package insert]. North Wales, PA: Teva Pharmaceuticals; 2015.
44. Ait-Daoud N, Johnson BA. Medications for the treatment of alcoholism. In: Johnson BA, Ruiz P, Galanter M, eds. Handbook of Clinical Alcoholism Treatment. Lippincott Williams & Wilkins, Baltimore; 2003
45. Laaksonen E, Koski-Jännes A, Salaspuro M, Ahtinen H, Alho H. A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence. Alcohol Alcohol. 2008;43(1):53-61.
46. Skinner MD, Lahmek P, Pham H, Aubin HJ. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One. 2014;9(2):e87366.
47. Jørgensen CH, Pedersen B, Tønnesen H. The efficacy of disulfiram for the treatment of alcohol use disorder. Alcohol Clin Exp Res. 2011;35(10):1749-1758.
48. Arbaizar B, Diersen-Sotos T, Gómez-Acebo I, Llorca J. Topiramate in the treatment of alcohol dependence: a meta-analysis. [Article in English, Spanish] Actas Esp Psiquiatr. 2010;38(1):8-12.
49. Johnson BA, Ait-Daoud N. Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients. Curr Pharm Des. 2010;16(19):2103-2112.
50. Paparrigopoulos T, Tzavellas E, Karaiskos D, Kourlaba G, Liappas I. Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study. BMC Psychiatry. 2011;11:41.
51. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361(9370):1677-1685.
52. Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch Gen Psychiatry. 2004;61(9):905-912.
53. Johnson BA, Rosenthal N, Capece JA, et al; Topiramate for Alcoholism Advisory Board; Topiramate for Alcoholism Study Group. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298(14):1641-1651.
54. Flórez G, García-Portilla P, Alvarez S, Saiz PA, Nogueiras L, Bobes J. Using topiramate or naltrexone for the treatment of alcohol-dependent patients. Alcohol Clin Exp Res. 2008;32(7):1251-1259.
55. Flórez G, Saiz PA, Garcia-Portilla P, Alvarez S, Nogueiras L, Bobes J. Topiramate for the treatment of alcohol dependence: comparison with naltrexone. E ur Addict Res. 2011;17(1):29-36.
56. Baltieri DA, Daró FR, Ribeiro PL, de Andrade AG. Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction. 2008;103(12):2035-2044.
57. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia. 2000;41(suppl 1):S17-S20.
58. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res. 1997;28(3):167-179.
59. Guglielmo R, Martinotti G, Quatrale M, et al. Topiramate in alcohol use disorders: review and update. CNS Drugs. 2015;29(5):383-395.
60. Kranzler HR, Covault J, Feinn R, et al. Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry . 2014;171(4):445-452.
61. Batki SL, Pennington DL, Lasher B, et al. Topiramate treatment of alcohol use disorder in veterans with posttraumatic stress disorder: a randomized controlled pilot trial. Alcohol Clin Exp Res. 2014;38(8):2169-2177.
62. Topamax [package insert]. Titusville, NJ: Janssen Pharmaceuticals Inc; 2017.
63. Meador KJ. Cognitive effects of levetiracetam versus topiramate. Epilepsy Curr. 2008;8(3):64-65.
64. Luykx JJ, Carpay JA. Nervous system adverse responses to topiramate in the treatment of neuropsychiatric disorders. Expert Opin Drug Saf. 2010;9(4):623-631.
65. The Management of Substance Use Disorder Work Group; US Department of Veteran Affairs, US Department of Defense. VA/DoD clinical practice guideline for the management of substance use disorders. https://www.healthquality.va.gov/guidelines/MH/sud/VADODSUDCPGRevised22216.pdf. Published December 2015. Accessed September 12, 2018.
66. Sills GJ. The mechanism of action of gabapentin and pregabalin. Curr Opin Pharmacol. 2006;6(1):108-113.
67. Mason BJ, Quello S, Goodell V, Shandan F, Kyle M, Begovic A. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med. 2014;174(1):70-77.
68. Anton RF, Myrick H, Wright TM, et al. Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry. 2011;168(7):709-717.
69. Neurontin [package insert]. New York, NY: Pfizer; 2017.
70. American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227-2246.
71. Addolorato G, Leggio L. Safety and efficacy of baclofen in the treatment of alcohol-dependent patients. Curr Pharm Des. 2010;16(19):2113-2117.
72. Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: a randomized, double-blind, controlled study. Lancet. 2007;370(9603):1915-1922.
73. Dore GM, Lo K, Juckes L, Bezyan S, Latt N. Clinical experience with baclofen in the management of alcohol-dependent patients with psychiatric comorbidity: a selected cases series. Alcohol Alcohol. 2011;46(6):714-720.
74. Baclofen tablet [package insert]. Pulaski, TN: AvKare Inc; 2018.
75. Hansel DE, Hansel CR, Shindle MK, et al. Oral baclofen in cerebral palsy: possible seizure potentiation? Pediatr Neurol. 2003;29(3):203-206.
76. Leggio L, Ferrulli A, Zambon A, et al. Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection. Addict Behav. 2012;37(4):561-564.
77. Zofran [package insert]. East Hanover, NJ: Norvartis Pharmaceuticals; 2017.
78. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999;38(8):1083-1152.
79. Johnson BA, Campling GM, Griffiths P, Cowen PJ. Attenuation of some alcohol-induced mood changes and the desire to drink by 5-HT3 receptor blockade: a preliminary study in health male volunteers. Psychopharmacology (Berl). 1993;112(1):142-144.
80. Johnson B, Roache J, Javors M, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA. 2000;284(8):963-971.
81. Kasinath NS, Malak O, Tetzlaff J. Atrial fibrillation after ondansetron for the prevention and treatment of postoperative nausea and vomiting: a case report. Can J Anaesth. 2003;50(3):229-231.
82. Sellers EM, Toneatto T, Romach MK, Somer GR, Sobell LC, Sobell MB. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res. 1994;18(4):879-885.
83. Havrilla PL, Kane-Gill SL, Verrico MM, Seybert AL, Reis SE. Coronary vasospasm and atrial fibrillation associated with ondansetron therapy. Ann Pharmacother. 2009;43(3):532-536.
84. Donoghue K, Elzerbi C, Saunders R, Whittington C, Pilling S, Drummond C. The efficacy of acamprosate and naltrexone in the treatment alcohol dependence, Europe versus the rest of the world: a meta-analysis. Addiction. 2015;110(6):920-930.
85. National Institute for Health and Care Excellence. Alcohol-use disorder: diagnosis, assessment and management of harmful drinking and alcohol dependence. Clinical guideline [CG115]. https://www.nice.org.uk/guidance/cg115. Published February 2011. Accessed September 12, 2018.
86. U.S. Department of Health and Human Services, National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism. Helping patients who drink too much a clinician’s guide. https://www.niaaa.nih.gov/guide. Accessed September 12, 2018.
87. Blodgett JC, Del Re AC, Maisel NC, Finney JW. A meta-analysis of topiramate’s effects for individuals with alcohol use disorders. Alcohol Clin Exp Res. 2014;38(6):1481-1488.
88. Müller CA, Geisel O, Pelz P, et al. High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial. Eur Neuropsychopharmacol. 2015;25(8):1167-1177.
89. Beraha EM, Salemink E, Goudriaan AE, et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomized, double-blind controlled trial. Eur Neuropsychopharmacol. 2016;26(12):1950-1959.
90. DeVido J, Bogunovic O, Weiss RD. Alcohol use disorders in pregnancy. Harv Rev Psychiatry. 2015;23(2)112-121.
91. Anton RF, Moak DH, Latham P, et al. Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol. 2005;25(4):349-357.
92. Harris AHS, Bowe T, Hagedorn H, et al. Multifaceted academic detailing program to increase pharmacotherapy for alcohol use disorder: interrupted time series evaluation of effectiveness. Addict Sci Clin Pract. 2016;11(1):15.
